Beam Therapeutics (NASDAQ:BEAM) Shares Down 10.4% - What's Next?

Key Points

• BEAM shares fell 10.4% to about $24.20 on Tuesday, with trading volume 65% below its average.
• Beam reported positive pivotal BEACON trial results for risto-cel in sickle cell disease, meeting key efficacy and safety endpoints; the company said the results support a potential U.S. biologics license application by year-end 2026.
• The latest quarterly results missed expectations: Beam reported a loss of $1.28 per share and revenue of $0.31 million versus analysts’ estimates of a $1.17 loss per share and $8.75 million in revenue. Analysts’ average rating remained “Moderate Buy,” with a $47.36 average price target.

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) was down 10.4% during trading on Tuesday. The company traded as low as $24.33 and last traded at $24.2040. Approximately 702,542 shares were traded during mid-day trading, a decline of 65% from the average daily volume of 2,025,225 shares. The stock had previously closed at $27.02.

Key Stories Impacting Beam Therapeutics

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Beam reported positive topline pivotal data from its BEACON Phase 1/2 trial of risto-cel in patients with sickle cell disease. The study met its primary efficacy endpoint—freedom from severe vaso-occlusive crises for at least 12 consecutive months—as well as primary safety and secondary endpoints. Beam said the results support a planned U.S. biologics license application submission, potentially by year-end 2026. Article: Positive topline BEACON trial data
• Positive Sentiment: HC Wainwright, which maintains a Buy rating, raised its earnings-per-share estimates across several quarters and fiscal years. The revisions were modest but generally imply slightly smaller expected losses. Article: HC Wainwright estimate revisions

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on BEAM shares. Guggenheim decreased their target price on shares of Beam Therapeutics from $55.00 to $51.00 and set a "buy" rating on the stock in a report on Thursday, November 5th. Canaccord Genuity Group lowered their price objective on Beam Therapeutics from $79.00 to $78.00 and set a "buy" rating for the company in a research report on Wednesday, November 4th. Wedbush raised their target price on Beam Therapeutics from $28.00 to $30.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 4th. Weiss Ratings restated a "sell (d-)" rating on shares of Beam Therapeutics in a research report on Thursday, October 15th. Finally, William Blair raised Beam Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $47.36.

Beam Therapeutics Stock Down 9.9%

The business's 50 day moving average price is $25.53 and its 200-day moving average price is $28.00. The firm has a market capitalization of $2.52 billion, a PE ratio of -23.46 and a beta of 2.23. The company has a debt-to-equity ratio of 0.11, a quick ratio of 14.57 and a current ratio of 13.01.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($1.28) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.11). Beam Therapeutics had a negative return on equity of 32.76% and a negative net margin of 73.04%. The company had revenue of $0.31 million for the quarter, compared to analysts' expectations of $8.75 million. During the same period in the previous year, the business posted ($1.10) EPS. The business's revenue for the quarter was down 96.8% on a year-over-year basis. As a group, equities research analysts forecast that Beam Therapeutics Inc. will post -4.66 earnings per share for the current year.

Insider Activity at Beam Therapeutics

In other news, CEO John Evans sold 25,000 shares of the firm's stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $23.57, for a total transaction of $589,250.00. Following the completion of the transaction, the chief executive officer directly owned 1,047,205 shares in the company, valued at $24,682,621.85. This trade represents a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 3.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Beam Therapeutics

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Beam Therapeutics in the 2nd quarter valued at about $308,796,000. ARCH Venture Management LLC acquired a new stake in shares of Beam Therapeutics during the second quarter worth about $155,771,929. Dimensional Fund Advisors LP boosted its stake in shares of Beam Therapeutics by 10.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,154,575 shares of the company's stock valued at $51,327,000 after purchasing an additional 206,696 shares during the period. ADAR1 Capital Management LLC purchased a new position in shares of Beam Therapeutics in the first quarter valued at approximately $34,467,000. Finally, Bank of America Corp DE acquired a new position in shares of Beam Therapeutics in the second quarter valued at approximately $24,733,000. Institutional investors and hedge funds own 99.68% of the company's stock.

Beam Therapeutics Company Profile

Beam Therapeutics is a biotechnology company developing genetic medicines using base editing, a form of gene editing designed to make precise changes to DNA. Its platform includes base-editing technologies and delivery systems intended to address diseases by altering the genetic instructions involved in their development. The company's research and development programs include potential treatments for genetic diseases, including sickle cell disease. Its work spans medicines made by editing a patient's cells outside the body as well as approaches intended to deliver gene editing directly to cells in the body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.